Related Experiment Video
Updated: Jul 12, 2026
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
A DNA aptamer targeting RANKL and its nanoparticle-mediated delivery ameliorate osteoporotic bone loss
Yang Yang1, Zhuqing Wan1, Xiaodong Guo1
1Department of Prosthodontics, Peking University School and Hospital of Stomatology, Beijing, 100081, China; National Center of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing Key Laboratory for Intelligent Biomanufacturing and Regeneration of Craniofacial Tissues, China.
A novel nanomedicine therapy, aptRANKL@MSN, effectively reverses osteoporosis by targeting RANKL. This targeted approach improves bone mass and strength with minimal toxicity, offering a promising new treatment for bone disease.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Orthopedics
Background:
- Osteoporosis management is hindered by poor drug bioavailability in bone and systemic side effects.
- Current treatments for osteoporosis lack targeted delivery and efficient bone accumulation.
- RANKL (Receptor Activator of Nuclear Factor kappa-B Ligand) is a key regulator of bone resorption.
Purpose of the Study:
- To develop and evaluate a targeted nanomedicine, aptRANKL@MSN, for osteoporosis treatment.
- To assess the efficacy and safety of aptRANKL@MSN in a mouse model of osteoporosis.
- To investigate the potential of aptRANKL@MSN to rebalance bone homeostasis.
Main Methods:
- Engineering of aptRANKL@MSN by conjugating a RANKL-binding DNA aptamer to PEGylated mesoporous silica nanoparticles (MSNs).
- Evaluation of aptRANKL@MSN in an ovariectomized mouse model of osteoporosis.
- Assessment of bone mass, microarchitecture, mechanical strength, bone resorption markers, bone formation markers, and toxicity.
Main Results:
- aptRANKL@MSN treatment significantly reversed bone loss, restoring bone mass, microarchitecture, and mechanical strength.
- The therapy demonstrated dual action, suppressing bone resorption and enhancing bone formation.
- aptRANKL@MSN showed superior efficacy compared to free aptamer and alendronate with no significant toxicity.
Conclusions:
- aptRANKL@MSN is a precise and potent nanomedicine for osteoporosis.
- The bone-accumulating nanoparticle platform enhances therapeutic efficacy and reduces systemic side effects.
- This targeted therapy holds strong potential for clinical translation in managing osteoporosis.